PMID- 20144337
OWN - NLM
STAT- MEDLINE
DCOM- 20100602
LR  - 20211020
IS  - 1932-2968 (Electronic)
IS  - 1932-2968 (Linking)
VI  - 3
IP  - 4
DP  - 2009 Jul 1
TI  - A minimal C-peptide sampling method to capture peak and total prehepatic insulin 
      secretion in model-based experimental insulin sensitivity studies.
PG  - 875-86
AB  - AIMS AND BACKGROUND: Model-based insulin sensitivity testing via the intravenous 
      glucose tolerance test (IVGTT) or similar is clinically very intensive due to the 
      need for frequent sampling to accurately capture the dynamics of insulin 
      secretion and clearance. The goal of this study was to significantly reduce the 
      number of samples required in intravenous glucose tolerance test protocols to 
      accurately identify C-peptide and insulin secretion characteristics. METHODS: 
      Frequently sampled IVGTT data from 12 subjects [5 normal glucose-tolerant (NGT) 
      and 7 type 2 diabetes mellitus (T2DM)] were analyzed to calculate insulin and 
      C-peptide secretion using a well-accepted C-peptide model. Samples were reduced 
      in a series of steps based on the critical IVGTT profile points required for the 
      accurate estimation of C-peptide secretion. The full data set of 23 measurements 
      was reduced to sets with six or four measurements. The peak secretion rate and 
      total secreted C-peptide during 10 and 20 minutes postglucose input and during 
      the total test time were calculated. Results were compared to those from the full 
      data set using the Wilcoxon rank sum to assess any differences. RESULTS: In each 
      case, the calculated secretion metrics were largely unchanged, within expected 
      assay variation, and not significantly different from results obtained using the 
      full 23 measurement data set (P < 0.05). CONCLUSIONS: Peak and total C-peptide 
      and insulin secretory characteristics can be estimated accurately in an IVGTT 
      from as few as four systematically chosen samples, providing an opportunity to 
      minimize sampling, cost, and burden.
CI  - Copyright 2009 Diabetes Technology Society.
FAU - Lotz, Thomas
AU  - Lotz T
AD  - Department of Mechanical Engineering, Centre for Bio-Engineering, University of 
      Canterbury, Christchurch, New Zealand.
FAU - Goltenbott, Uli
AU  - Goltenbott U
FAU - Chase, J Geoffrey
AU  - Chase JG
FAU - Docherty, Paul
AU  - Docherty P
FAU - Hann, Christopher E
AU  - Hann CE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090701
PL  - United States
TA  - J Diabetes Sci Technol
JT  - Journal of diabetes science and technology
JID - 101306166
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Blood Glucose/analysis
MH  - C-Peptide/analysis/*metabolism
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Insulin/administration & dosage/analysis/*metabolism
MH  - Insulin Infusion Systems
MH  - Insulin Resistance
MH  - Insulin Secretion
MH  - Time Factors
PMC - PMC2769977
EDAT- 2010/02/11 06:00
MHDA- 2010/06/03 06:00
PMCR- 2010/07/01
CRDT- 2010/02/11 06:00
PHST- 2010/02/11 06:00 [entrez]
PHST- 2010/02/11 06:00 [pubmed]
PHST- 2010/06/03 06:00 [medline]
PHST- 2010/07/01 00:00 [pmc-release]
AID - dst.3.4.0875 [pii]
AID - 10.1177/193229680900300435 [doi]
PST - epublish
SO  - J Diabetes Sci Technol. 2009 Jul 1;3(4):875-86. doi: 10.1177/193229680900300435.